Liposomal doxorubicin with and without TNFα in the perfusional treatment of advanced soft tissue limb sarcoma: Preliminary results

In Vivo

Volumn 20, Issue 6 A, 2006, Pages 735-738

  Di Filippo, Franco ^a   Anzà, Michele ^a   Garinei, Rosa ^a   Cavaliere, Francesco ^a   Perri, Pasquale ^a   Botti, Claudio ^a   Di Angelo, Piera ^a   Di Filippo, Simona ^a   Maini, Carlo Ludovico ^a   Pasqualoni, Rossella ^a   Di Segni, Susanna ^a   Colantonio, Simona ^a   Bruno, Pietro ^a   Piarulli, Loredana ^a   Principi, Francesca ^a  

^a REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Caelyx ; Perfusion; Soft tissue sarcoma

Indexed keywords

DOXORUBICIN; TUMOR NECROSIS FACTOR ALPHA; ANTINEOPLASTIC AGENT;

ABSENCE OF SIDE EFFECTS; ADULT; ADVANCED CANCER; AGED; ALVEOLAR SOFT PART SARCOMA; ANGIOSARCOMA; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG RESPONSE; FEMALE; HUMAN; HUMAN TISSUE; HYPERTHERMIC THERAPY; LEIOMYOSARCOMA; LIMB DISEASE; LIMB PERFUSION; LIPOSARCOMA; LOW DRUG DOSE; MALE; MALIGNANT FIBROUS HISTIOCYTOMA; MAXIMUM TOLERATED DOSE; MEDICAL DOCUMENTATION; MONOTHERAPY; PATIENT SATISFACTION; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; SOFT TISSUE SARCOMA; SYNOVIAL SARCOMA; TUMOR NECROSIS; UNSPECIFIED SIDE EFFECT; DOSE RESPONSE; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PATHOLOGY; REGIONAL PERFUSION; SARCOMA; SOFT TISSUE TUMOR; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, CANCER, REGIONAL PERFUSION; COMBINED MODALITY THERAPY; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; FEMALE; HUMANS; MALE; MIDDLE AGED; SARCOMA; SOFT TISSUE NEOPLASMS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33846070749     PISSN: 0258851X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Di Filippo F, Rossi CR, Vaglini M, Azzarelli A, Anzà M, Santinami M, Lise M, Cavaliere F, Giannarelli D, Quagliuolo V, Vecchiato A, Deraco M, Garinei R, Foletto M, Botti C and Cavaliere R: Hyperthermic antiblastic perfusion with alpha tumor necrosis factor and doxorubicin for the treatment of soft tissue limb sarcoma in candidates for amputation: results of a phase I study. J Immunother 22(5): 407-414, 1999.
2. Di Filippo F, Garinei R, Anzà M, Cavaliere F, Giannarelli D, Cagol PP, Rossi CR, Santinami M, Deraco M, Botti C, Perri P, Di Filippo S, Piarulli L and Bruno P: Doxorubicin in isolated limb perfusion in the treatment of advanced limb soft tissue sarcoma. J Exp Clin Cancer Res 22(4): 81-87, 2003.
3. Gabizon A, Shmeeda H and Barenholz Y: Pharmacokinetics of pegylated liposomal Doxorubicin: review of animal and human studies. Clin Pharmacokinet 42(5): 419-436, 2003.
4. Baba H: Effect of whole body hyperthermia combined with adriamycin on tumor and normal tissue in rats. 37th Annual Meeting of the Radiation Research Society and 9th Annual Meeting of the North American Hyperthermia Group. March 18-22, Seattle, WA, 34, 1989.
5. Alexander RB, Nelson WG and Coffey DS: Synergistic enhancement by tumor necrosis factor of in vitro cytotoxicity from chemotherapeutic drugs targeted at DNA topoisomerase II. Cancer Res 47(9): 2403-2406, 1987.
6. Niitsu Y, Watanabe N, Umeno H, Sone H, Neda H, Yamauchi N, Maeda M and Urushizaki I: Synergistic effects of recombinant human tumor necrosis factor and hyperthermia on in vitro cytotoxicity and artificial metastasis. Cancer Res 48(3): 654-657, 1988.
7. Di Filippo F, Cavaliere F, Anzà M, Garinei R, Botti C, Perri P, Di Angelo P, Patrizi V, Di Filippo S and Vista P: Liposomal doxorubicin in the perfusional treatment of advanced soft tissue limb sarcoma. J Chem 16(5): 66-69, 2004.
8. Wieberdink J, Benckhuysen C, Braat RP, van Slooten EA and Olthuis GA: Dosimetry in isolated perfusion of the limbs by assessment of perfused tissue volume and grading of toxic tissue reaction. Eur J Cancer Clin Oncol 18(10): 905-910, 1982.
9. Di Filippo F, Calabrò AM, Cavallari A, Carlini S, Buttini GL, Moscarelli F, Cavaliere F, Piarulli L and Cavaliere R: The role of hyperthermic perfusion as a first step in the treatment of soft tissue sarcoma of the extremities. World J Surg 12(3): 332-338, 1988.
10. Casara D, Rubello D, Pilati PP, Scalerta R, Foletto M and Rossi CR: Optimized procedure of real-time systemic leakage monitoring during isolated limb perfusion using a hand held gamma probe and 99mTc-HAS. Nucl Med Commun 25(1): 61-66, 2004.
11. Swenson CE, Bolcsak LE, Batist G, Guthrie TH Jr, Tkaczuk KH, Boxenbaum H, Welles L, Chow SC, Bhamra R and Chaikin P: Pharmacokinetics of doxorubicin administered i.v. as Myocet (TLC D-99; liposome-encapsulated doxorubicin citrate) compared with conventional doxorubicin when given in combination with cyclophosphamide in patients with metastatic breast cancer. Anticancer Drugs 14(3): 239-246, 2003.
12. Ten Hagen TL, Van der Veen, Seynhaeve AL, van Tiel ST and Eggermont AM: Pegylated liposomal tumor necrosis factor-alpha results in reduced toxicity and synergistic antitumor activity after systemic administration in combination with liposomal doxorubicin (Doxil) in soft tissue sarcoma-bearing rats. Int J Cancer 87(6): 829-837, 2000.
13. Brouckaert P, Takahashi N, van Tiel ST, Hostens J, Eggermont AM, Seynhaeve AL, Fiers W and ten Hagen TL: Tumor necrosis factor-alpha augmented tumor response in B16 BL6 melanoma-bearing mice treated with stealth liposomal doxorubicin (Doxil) correlates with altered Doxil Pharmacokinetics. Int J Cancer 109(3): 442-448, 2004.